🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

RecruitingEARLY Phase 1Ages 18 Years - 60 YearsAllVanderbilt University Medical Center
NCT06609356 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to understand the heart and blood sugar health benefits of using an adjunctive therapy to lower high insulin levels in people with type 1 diabetes. The investigators will also look at people with a specific type of diabetes called Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY) and those without diabetes to help interpret the results. The investigators will use a medication that helps the body get rid of sugar, called and SGLT2 inhibitor, with the goal to reduce the body's insulin requirements. The investigators believe this could lead to better heart and blood sugar health, including a better response to insulin and more available nitric oxide, a gas that helps blood vessels function well. The investigators will compare heart and blood sugar health risk factors in participants with type 1 diabetes, participants with Glucokinase-Maturity Onset Diabetes of the

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Age: 18-60 years BMI: 18-28 kg/m² Weight: ≥ 50 kg T1DM Participants: Duration of T1DM: 1-30 years HbA1c: 5.7-7.5% Insulin Therapy: Using automated insulin delivery GCK-MODY Participants: HbA1c: 5.7-7.5% Genetic Confirmation: Positive GCK sequencing Control Participants: HbA1c: less than 5.5% \*\* Exclusion Criteria: Severe Hypoglycemia: ≥1 episode in the past 3 months Comorbidities: * Any hospital admissions for diabetic ketoacidosis in the past 6 months * SBP greater than 140 mmHg and DBP greater than 100 mmHg * eGFR by MDRD equation of less than 60 mL/min/1.73 m² * AST or ALT greater than 2.5 times ULN * Hct less than 35% Medications: * Any antioxidant vitamin supplement within 2 weeks before the study * Any systemic glucocorticoid * Antipsychotics * Atenolol, Metoprolol, Propranolol * Niacin * Any thiazide diuretic * Any oral contraceptive pill with greater than 35 mcg ethinyl estradiol * Growth hormone * Any immunosuppressant * Antihypertensive * Any antihyperlipidemic Other: * Pregnancy * Tanner stage less than 5 * Peri- or post-menopausal women * Active smoker T1DM Participants: Medications: Any diabetes medication except insulin C-peptide: greater than 0.7 ng/mL (fasting) GCK-MODY Participants: None specific
💊

What it tests

  • Study Visit 1
  • Placebo
  • Study Visit 2
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
📍

Where

1 site
Vanderbilt University Medical Center
Nashville, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy